NNC 45-0095
NC 45-0095 is a synthetic nonsteroidal selective estrogen receptor modulator which was under development by Novo Nordisk for the treatment of postmenopausal osteoporosis but was never marketed. It is a partial agonist of the estrogen receptor with mixed estrogenic and antiestrogenic activity, and shows full estrogenic activity in bone and uterus. The compound is a pyrrolo indolizine derivative. Its development was discontinued by 2003.